The Biologics News and Reports Portal

Show Cart

Biosimilar Antibodies & Proteins

Results 11 - 20 of 22

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

1,300.00 €

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

500.00 €

Feb 2016 Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

200.00 €

Jul 2015 Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

400.00 €

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

1,462.50 €

1,950.00 €

(Discount: 25.00%)

May 2013 Competitor Analysis: Thrombolytics & Fibrinolytics

250.00 €

May 2013 Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

1,600.00 €

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Shopping cart

Cart empty

Latest report

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Featured Products

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs:a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Biosimilar Antibodies & Proteins

May 2016 Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

May 2016 Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

Feb 2016 Competitor Analysis: PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors

Jul 2015 Filgrastim & Pegfilgrastim Biosimilars & Biosuperiors 2015 – a G-CSF & GM-CSF Competitor Analysis

Jul 2014 Botulinum Neurotoxins: A comparative industry analysis of products, pipelines, technologies and stakeholders

May 2013 Competitor Analysis: Thrombolytics & Fibrinolytics

May 2013 Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors

Apr 2013 Competitor Analysis: Insulin

Apr 2013 Competitor Analysis: Interferon

Apr 2013 Competitor Analysis: Thrombopoiesis Stimulating Agents (TPO and IL-11)

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing